archetype (adl_version=1.4; uid=37eb0766-c6ca-4a6f-8285-b682ac74e60c)
	openEHR-EHR-EVALUATION.hormone_therapy_for_prostate_cancer_assessment.v0

concept
	[at0000]

language
	original_language = <[ISO_639-1::en]>

description
	original_author = <
		["date"] = <"2025-12-15">
		["name"] = <"Kevin Arjona">
		["organisation"] = <"Cambio CDS">
		["email"] = <"kevin.arjona@cambio.se">
	>
	lifecycle_state = <"unmanaged">
	details = <
		["en"] = <
			language = <[ISO_639-1::en]>
			purpose = <"To assess the recorded risk group and endocrine treatment during radiation therapy.">
			keywords = <"prostate, cancer, radiation, therapy, radiotherapy, fractionation, risk, GnRH, anti-androgen, ADT, hormone", ...>
			copyright = <"© Cambio CDS">
			use = <"Use to assess the inputs recorded in the hormone_therapy_for_prostate_cancer.adl archetype.">
			misuse = <"Not to be used for recording the administration of the treatment. Not to be used for hormone therapy recommendations in other types of cancer.">
		>
	>
	other_details = <
		["licence"] = <"This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/.">
		["custodian_organisation"] = <"openEHR Foundation">
		["original_namespace"] = <"org.openehr">
		["original_publisher"] = <"openEHR Foundation">
		["custodian_namespace"] = <"org.openehr">
		["references"] = <"Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Erratum in: Lancet. 2009 Apr 4;373(9670):1174. PMID: 19091394.

Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012 Aug;62(2):213-9. doi: 10.1016/j.eururo.2012.03.053. Epub 2012 Apr 3. PMID: 22502942.

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8. PMID: 21440505.

Nationellt vårdprogram prostatacancer [Internet]. Regionala cancercentrum i samverkan; 2023 [cited 2025 Nov 24]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/">
		["build_uid"] = <"f481de37-2547-3172-8091-1bded44d1005">
	>

definition
	EVALUATION[at0000] matches {    -- Hormone therapy for prostate cancer assessment
		data matches {
			ITEM_TREE[at0003] matches {    -- Item tree
				items cardinality matches {0..*; unordered} matches {
					ELEMENT[at0004] occurrences matches {0..1} matches {    -- Recommendation status
						value matches {
							DV_CODED_TEXT matches {
								defining_code matches {
									[local::
									at0006,    -- Recommended
									at0007,    -- Not recommended
									at0008]    -- Consider/Conditional
								}
							}
						}
					}
					ELEMENT[at0010] occurrences matches {0..1} matches {    -- Comment
						value matches {
							DV_CODED_TEXT matches {
								defining_code matches {
									[local::
									at0011,    -- Treatment with bicalutamide or GnRH agonist should continue for 2–3 years after radiotherapy
									at0012,    -- In case the pelvic lymph nodes are to be treated and PSA < 0.7 µg/l (If PSA > 0.7, 2 years of bicalutamide is recommended)
									at0013]    -- In selected cases in patients who are willing to accept the side effects or who cannot tolerate bicalutamide
								}
							}
						}
					}
				}
			}
		}
		protocol matches {
			ITEM_TREE[at0001] matches {    -- Item tree
				items cardinality matches {0..*; unordered} matches {
					allow_archetype CLUSTER[at0002] occurrences matches {0..1} matches {    -- Extension
						include
							archetype_id/value matches {/.*/}
					}
				}
			}
		}
	}

ontology
	term_definitions = <
		["en"] = <
			items = <
				["at0000"] = <
					text = <"Hormone therapy for prostate cancer assessment">
					description = <"Assessment of the hormone therapy (ADT) when given in conjunction with radiation therapy for prostate cancer.">
					comment = <"Original version, c 2009">
				>
				["at0001"] = <
					text = <"Item tree">
					description = <"@ internal @">
				>
				["at0002"] = <
					text = <"Extension">
					description = <"Additional information required to extend the model with local content or to align with other reference models or formalisms.">
					comment = <"For example: local information requirements; or additional metadata to align with FHIR.">
				>
				["at0003"] = <
					text = <"Item tree">
					description = <"@ internal @">
				>
				["at0004"] = <
					text = <"Recommendation status">
					description = <"">
				>
				["at0006"] = <
					text = <"Recommended">
					description = <"">
				>
				["at0007"] = <
					text = <"Not recommended">
					description = <"">
				>
				["at0008"] = <
					text = <"Consider/Conditional">
					description = <"">
				>
				["at0010"] = <
					text = <"Comment">
					description = <"">
				>
				["at0011"] = <
					text = <"Treatment with bicalutamide or GnRH agonist should continue for 2–3 years after radiotherapy">
					description = <"">
				>
				["at0012"] = <
					text = <"In case the pelvic lymph nodes are to be treated and PSA < 0.7 µg/l (If PSA > 0.7, 2 years of bicalutamide is recommended)">
					description = <"">
				>
				["at0013"] = <
					text = <"In selected cases in patients who are willing to accept the side effects or who cannot tolerate bicalutamide">
					description = <"">
				>
			>
		>
	>
